Chengjiao Liu
Overview
Explore the profile of Chengjiao Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jia H, Mai J, Wu M, Chen H, Li X, Li C, et al.
BMC Med
. 2023 Mar;
21(1):98.
PMID: 36927420
Background: Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of...
2.
Zhang H, Fan Y, Gao L, Wang B, Xu T, Wu M, et al.
Expert Opin Investig Drugs
. 2022 Dec;
31(11):1255-1263.
PMID: 36537742
Objective: KN015 is a long-acting, recombinant human follicle-stimulating hormone Fc fusion protein that induces follicle development. This first-in-human study evaluated the effect of KN015 on healthy, pituitary-suppressed women and examined...
3.
Zhang H, Gao L, Lou J, Wu M, Chen H, Yang L, et al.
Front Pharmacol
. 2022 Jun;
13:873588.
PMID: 35662718
Hepenofovir, a novel hepatic targeting prodrug of tenofovir, has been developed for the treatment of chronic hepatitis B (CHB). This is a first-in-human study to evaluate the pharmacokinetics (PK) and...
4.
Li X, Li Q, Ji T, Zhang H, Liu J, Wu M, et al.
Expert Opin Investig Drugs
. 2022 May;
31(7):729-736.
PMID: 35574691
Background: This is the first-in-human study to evaluate the pharmacokinetics, safety, and tolerability of TQC3564 (a novel CRTh2 receptor antagonist) in healthy Chinese subjects. Research Design And Methods: This project...
5.
Zhang H, Daoud S, Gillen M, Calderon N, Heijer M, Molins E, et al.
Drugs R D
. 2022 Feb;
22(1):35-42.
PMID: 35133636
Background And Objectives: The aim of this study was to evaluate the pharmacokinetics, safety, and tolerability of aclidinium bromide/formoterol fumarate in patients from China with moderate-to-severe chronic obstructive pulmonary disease...
6.
Hu Y, Zhang H, Wu M, Liu J, Li X, Zhu X, et al.
Expert Opin Investig Drugs
. 2021 Jan;
30(3):263-269.
PMID: 33405993
Background & Aims: TQ-A3334, a selective, oral toll-like receptor (TLR)-7 agonist, is being developed to treat chronic hepatitis B (CHB). This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD)...
7.
Zhang H, Hu Y, Wu M, Liu J, Zhu X, Li X, et al.
Aliment Pharmacol Ther
. 2020 Nov;
53(2):243-252.
PMID: 33249630
Background: HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. Aims: To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in...
8.
Zhang H, Wu M, Zhu X, Li C, Li X, Sun J, et al.
Front Pharmacol
. 2020 Nov;
11:01329.
PMID: 33132906
Objective: This study was conducted to explore the tolerance, variability, pharmacokinetics (PK), and pharmacodynamics (PD) of denosumab biosimilar (QL1206) in healthy Chinese subjects. Methods: This is a randomized, double-blind, two-arm,...
9.
Zhang H, Wu M, Zhu X, Li C, Li X, Jin W, et al.
Antiviral Res
. 2019 Dec;
174:104693.
PMID: 31838002
Background & Aims: Pradefovir is a liver targeted novel prodrug of adefovir (PMEA) developed to provide higher antiviral activity with reduced systemic toxicities. This study evaluated the tolerability, pharmacokinetics, and...
10.
Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al.
Diabetes Obes Metab
. 2019 Oct;
22(2):191-202.
PMID: 31588657
Aims: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of rongliflozin in a cohort of healthy Chinese people and people with type 2 diabetes mellitus (T2DM). Materials And Methods:...